Close Menu

Oxford Nanopore

Oxford Nanopore Technologies was founded in 2005 to develop an electronic, single molecule sensing system based on nanopore science. The company now has more than 250 employees from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialization. Oxford Nanopore's instruments — MinIon, PromethIon, and GridIon are adaptable for the analysis of DNA, RNA, proteins, small molecules and other types of molecule.

Oxford Nanopore Facts

 

CEO: Gordon Sanghera

Website: www.nanoporetech.com

Ticker symbol: Privately held

Headquarters: Oxford, UK

Number of employees: 250+

Research teams at the University of California, Santa Cruz and the University of Washington have shown independently that biological nanopores can detect epigenetic modifications on individual bases within DNA strands.

After announcing an early-access program for its MinIon sequencer at the American Society of Human Genetics annual meeting in Boston last week, Oxford Nanopore Technologies showed off the device at its booth and gave a live demonstration of runs to a select group of potential cus

NEW YORK (GenomeWeb News) – Oxford Nanopore Technologies plans to launch an early-access program for its MinIon sequencer in late November, the company said today.

NEW YORK (GenomeWeb News) – Oxford Nanopore Technologies today said that it has raised £40 million ($63.7 million) through a private placement of ordinary shares.

People in the News: Adam Lowe

Premium

Personalis has appointed Adam Lowe to vice president of marketing. Lowe previously served as vice president of commercial operations at Oxford Nanopore Technologies.

Last week, Base4 Innovation said it plans to collaborate with Hitachi to develop a solid-state nanopore sequencer.

Researchers from the University of Cambridge have demonstrated that they can build tunable nanopores — controlling both the size of the pore and the number of binding sites within it — using hybrid DNA origami structures on glass nanocapillaries, technology that Oxford Nanopore h

NEW YORK (GenomeWeb News) – Oxford Nanopore Technologies today issued a statement disputing remarks made by Illumina CEO Jay Flatley at an investment conference about his firm's relationship with Oxford.

NEW YORK (GenomeWeb News) – Oxford Nanopore Technologies said today in its annual report that a commercialization agreement it had with Illumina will terminate on June 30, 2016.

Researchers at the University of Oxford working with an alpha-hemolysin protein-based nanopore sequencing strategy have shown that it is possible to pass long RNA heteropolymers through alpha-hemolysin pores using an electric current.

Pages

The US Department of Justice has proposed a rule change to enable DNA to be collected from migrants, the Associated Press reports.

Bernard Fisher, a surgeon who changed how breast cancer is treated, has died at 101, the New York Times reports.

Washington Post columnist writes that she is skeptical about DNA-based diets.

In PNAS this week: recurrent inactivation of DEPDC5 in gastrointestinal stromal tumors, taxonomic reliability of GenBank sequences, and more.